Expression of TRAIL and TRAIL receptors in normal and malignant tissues
The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Lethal effect of the anti-Fas antibody in mice
Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., & Nagata, S. (1993) · Nature · doi:10.1038/364806a0 · Cited by 1,881
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12687 · Cited by 1,793
The Receptor for the Cytotoxic Ligand TRAIL
Pan, G., O'Rourke, K., Chinnaiyan, A. M., Gentz, R., Ebner, R., Ni, J., & Dixit, V. M. (1997) · Science · doi:10.1126/science.276.5309.111 · Cited by 1,767
Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors
Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., et al. (1997) · Science · doi:10.1126/science.277.5327.818 · Cited by 1,664
An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL
Pan, G., Ni, J., Wei, Y.-F., Yu, G.-L., Gentz, R., & Dixit, V. M. (1997) · Science · doi:10.1126/science.277.5327.815 · Cited by 1,496
Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL
Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14363 · Cited by 1,184
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL
Walczak, H. (1997) · The EMBO Journal · doi:10.1093/emboj/16.17.5386 · Cited by 1,130
KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene
Wu, G. S., Burns, T. F., McDonald, E. R., Jiang, W., Meng, R., Krantz, I. D., Kao, G., Gan, D.-D., Zhou, J.-Y., Muschel, R., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-141 · Cited by 1,083
Jo, M., Kim, T.-H., Seol, D.-W., Esplen, J. E., Dorko, K., Billiar, T. R., & Strom, S. C. (2000) · Nature Medicine · doi:10.1038/75045 · Cited by 843
Degli-Esposti, M. A., Dougall, W. C., Smolak, P. J., Waugh, J. Y., Smith, C. A., & Goodwin, R. G. (1997) · Immunity · doi:10.1016/s1074-7613(00)80399-4 · Cited by 821
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., et al. (2001) · Nature Medicine · doi:10.1038/86397 · Cited by 702
TRAIL Receptors 1 (DR4) and 2 (DR5) Signal FADD-Dependent Apoptosis and Activate NF-κB
Schneider, P., Thome, M., Burns, K., Bodmer, J.-L., Hofmann, K., Kataoka, T., Holler, N., & Tschopp, J. (1997) · Immunity · doi:10.1016/s1074-7613(00)80401-x · Cited by 696
Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.
Galle, P. R., Hofmann, W. J., Walczak, H., Schaller, H., Otto, G., Stremmel, W., Krammer, P. H., & Runkel, L. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.5.1223 · Cited by 692
A novel receptor for Apo2L/TRAIL contains a truncated death domain
Marsters, S. A., Sheridan, J. P., Pitti, R. M., Huang, A., Skubatch, M., Baldwin, D., Yuan, J., Gurney, A., Goddard, A. D., Godowski, P., et al. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00422-2 · Cited by 653
Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family
Degli-Esposti, M. A., Smolak, P. J., Walczak, H., Waugh, J., Huang, C.-P., DuBose, R. F., Goodwin, R. G., & Smith, C. A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.7.1165 · Cited by 629
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
Ichikawa, K., Liu, W., Zhao, L., Wang, Z., Liu, D., Ohtsuka, T., Zhang, H., Mountz, J. D., Koopman, W. J., Kimberly, R. P., et al. (2001) · Nature Medicine · doi:10.1038/91000 · Cited by 543
Smyth, M. J., Cretney, E., Takeda, K., Wiltrout, R. H., Sedger, L. M., Kayagaki, N., Yagita, H., & Okumura, K. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.6.661 · Cited by 512
Takeda, K., Smyth, M. J., Cretney, E., Hayakawa, Y., Kayagaki, N., Yagita, H., & Okumura, K. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011171 · Cited by 465
TRAIL: a molecule with multiple receptors and control mechanisms
Griffith, T. S., & Lynch, D. H. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80224-0 · Cited by 453
Martin-Villalba, A., Herr, I., Jeremias, I., Hahne, M., Brandt, R., Vogel, J., Schenkel, J., Herdegen, T., & Debatin, K.-M. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-10-03809.1999 · Cited by 434
Zhang, X. D., Franco, A., Myers, K., Gray, C. P., Nguyen, T., & Hersey, P. (1999) · PubMed · Cited by 385
Takimoto, R., & El-Deiry, W. S. (2000) · Oncogene · doi:10.1038/sj.onc.1203489 · Cited by 360
Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL−/− mice
Lamhamedi-Cherradi, S.-E., Zheng, S.-J., Maguschak, K. A., Peschon, J., & Chen, Y. H. (2003) · Nature Immunology · doi:10.1038/ni894 · Cited by 348
TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL
Screaton, G. R., Mongkolsapaya, J., Xu, X.-N., Cowper, A. E., McMichael, A. J., & Bell, J. I. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00297-1 · Cited by 325
Self-citationSingh, T. R., Shankar, S., Chen, X., Asim, M., & Srivastava, R. K. (2003) · PubMed · Cited by 270
Jones, E. Y., Mongkolsapaya, J., Grimes, J. M., Chen, N., Xu, X., Stuart, D. I., & Screaton, G. R. (1999) · Nature Structural Biology · doi:10.1038/14935 · Cited by 253
Self-citationFunctional Analysis of TRAIL Receptors Using Monoclonal Antibodies
Griffith, T. S., Rauch, C. T., Smolak, P. J., Waugh, J. Y., Boiani, N., Lynch, D. H., Smith, C. A., Goodwin, R. G., & Kubin, M. Z. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.5.2597 · Cited by 241
(2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)81130-3 · Cited by 208
Sedger, L. M., Glaccum, M. B., Schuh, J. C. L., Kanaly, S. T., Williamson, E., Kayagaki, N., Yun, T., Smolak, P. J., Le, T., Goodwin, R. G., et al. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200208)32:8<2246::aid-immu2246>3.0.co;2-6 · Cited by 208
Zhang, X. D., Franco, A. V., Nguyen, T., Gray, C. P., & Hersey, P. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.8.3961 · Cited by 207
Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4
Chuntharapai, A., Dodge, K., Grimmer, K., Schroeder, K., Marsters, S. A., Koeppen, H., Ashkenazi, A., & Kim, K. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.8.4891 · Cited by 202
Nimmanapalli, R., Perkins, C. L., Орландо, М., O'Bryan, E., Nguyen, D. N., & Bhalla, K. N. (2001) · PubMed · Cited by 201
Ganten, T. M., Haas, T. L., Sykora, J., Stahl, H., Sprick, M. R., Fas, S. C., Krueger, A., Weigand, M. A., Grosse-Wilde, A., Stremmel, W., et al. (2004) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401437 · Cited by 196
Takeda, K., Smyth, M. J., Cretney, E., Hayakawa, Y., Yamaguchi, N., Yagita∥, H., & Okumura, K. (2001) · Cellular Immunology · doi:10.1006/cimm.2001.1896 · Cited by 183
Critical roles of TRAIL in hepatic cell death and hepatic inflammation
Zheng, S.-J., Wang, P., Tsabary, G., & Chen, Y. H. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19255 · Cited by 173
Sheikh, M. S., Huang, Y., Fernández‐Salas, E., El‐Deiry, W. S., Friess, H., Amundson, S. A., Yin, J., Meltzer, S. J., Holbrook, N. J., & Fornace, A. J. (1999) · Oncogene · doi:10.1038/sj.onc.1202763 · Cited by 172
Involvement of TRAIL and its receptors in viral hepatitis
Mundt, B., Kühnel, F., Zender, L., Paul, Y., Tillmann, H., Trautwein, C., Peter Manns, M., & Kubicka, S. (2003) · The FASEB Journal · doi:10.1096/fj.02-0537fje · Cited by 141
Kelly, M. M., Hoel, B. D., & Voelkel‐Johnson, C. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.1.5.169 · Cited by 130
Dörr, J. R., Bechmann, I., Waiczies, S., Aktaş, O., Walczak, H., Krammer, P. H., Nitsch, R., & Zipp, F. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-04-j0001.2002 · Cited by 116
Nguyen, T., Zhang, X. D., & Hersey, P. (2001) · PubMed · Cited by 99
Lin, T.-Y., Gu, J. H., Zhang, L., Huang, X., Stephens, L. C., Curley, S. A., & Fang, B. (2002) · PubMed · Cited by 95
VS38: a new monoclonal antibody for detecting plasma cell differentiation in routine sections.
Turley, H., Jones, M., Erber, W. N., Mayne, K., Waele, M. D., & Gatter, K. C. (1994) · Journal of Clinical Pathology · doi:10.1136/jcp.47.5.418 · Cited by 92
Self-citationSträter, J., Walczak, H., Pukrop, T., von Müller, L., Hasel, C., Kornmann, M., Mertens, T., & Möller, P. (2002) · Gastroenterology · doi:10.1053/gast.2002.31889 · Cited by 87
TRAIL Death Pathway Expression and Induction in Thyroid Follicular Cells
Bretz, J. D., Rymaszewski, M., Arscott, P. L., Myc, A., Ain, K. B., Thompson, N. W., & Baker, J. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.33.23627 · Cited by 86
Expression ofTRAILand Its Receptors in Human Brain Tumors
Stephan, F., Köhler, U., Schackert, G., & Schackert, H. K. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0493 · Cited by 82
Normal Thymocyte Negative Selection in TRAIL-deficient Mice
Cretney, E., Uldrich, A. P., Berzins, S. P., Strasser, A., Godfrey, D. I., & Smyth, M. J. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030634 · Cited by 79
Simon, A. K., Williams, O., Mongkolsapaya, J., Jin, B., Xu, X. N., Walczak, H., & Screaton, G. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091100398 · Cited by 74
Self-citationApoptosis and autoimmune thyroid disease: following a TRAIL to thyroid destruction?
Bretz, J. D., & Baker, J. R. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01345.x · Cited by 61
Voelkel‐Johnson, C. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.3.398 · Cited by 45
Yamashita, Y., Shimada, M., Tanaka, S., Okamamoto, M., Miyazaki, J., & Sugimachi, K. (2002) · Human Gene Therapy · doi:10.1089/10430340252769798 · Cited by 34
Mouzakiti, A., & Packham, G. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04424.x · Cited by 27
Cited by
Recent progress in tumor pH targeting nanotechnology
Lee, E. S., Gao, Z., & Bae, Y. H. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.003 · Cited by 866
The TRAIL apoptotic pathway in cancer onset, progression and therapy
Johnstone, R. W., Frew, A. J., & Smyth, M. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2465 · Cited by 834
Lee, E. S., Gao, Z., Kim, D., Park, K., Kwon, I. C., & Bae, Y. H. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.04.024 · Cited by 400
Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers
Plummer, R., Attard, G., Pacey, S., Li, L., Razak, A., Perrett, R., Barrett, M., Judson, I., Kaye, S., Fox, N. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0950 · Cited by 247
Keogh, R. J., Harris, L. K., Freeman, A., Baker, P. N., Aplin, J. D., Whitley, G. S., & Cartwright, J. E. (2007) · Circulation Research · doi:10.1161/01.res.0000261352.81736.37 · Cited by 114
Metadata
- Authors
- DANIELS, R. A., TURLEY, H., KIMBERLEY, F. C., LIU, X. S., MONGKOLSAPAYA, J., CH'EN, P., XU, X. N., JIN, B., PEZZELLA, F., & SCREATON, G. R.
- Venue
- Cell Research
- Published
- 2005-06
- Volume
- 15
- Issue
- 6
- Pages
- 430-438
- ISSN
- 1001-0602 (ISSN-L)
- 1748-7838
- OpenAlex
- W2068049794
- Cited by
- 173
- References
- 55
- FWCI
- 2.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.